The scientist’s investigation covers issues in Surgery, Radiation therapy, Internal medicine, Prostate cancer and Nuclear medicine. His Surgery study frequently links to related topics such as Urology. Peter Hoskin interconnects Breast cancer, Performance status and Intention-to-treat analysis in the investigation of issues within Radiation therapy.
His study connects Oncology and Internal medicine. His work carried out in the field of Prostate cancer brings together such families of science as Placebo, Prostate, Radiology and Brachytherapy. His research investigates the link between Nuclear medicine and topics such as Magnetic resonance imaging that cross with problems in Cancer, Oxygenation, Carbogen Breathing, Blood flow and Multiparametric Magnetic Resonance Imaging.
His scientific interests lie mostly in Radiation therapy, Internal medicine, Brachytherapy, Oncology and Radiology. Radiation therapy is a primary field of his research addressed under Surgery. His work on Bladder cancer, Hypoxia and Carcinoma as part of his general Internal medicine study is frequently connected to Hazard ratio, thereby bridging the divide between different branches of science.
The Brachytherapy study combines topics in areas such as Cervical cancer, Prostate cancer and Nuclear medicine. He combines subjects such as Prostate and Urology with his study of Prostate cancer. The Lung cancer research Peter Hoskin does as part of his general Oncology study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
Peter Hoskin focuses on Radiation therapy, Radiology, Brachytherapy, Internal medicine and Prostate cancer. His research on Radiation therapy also deals with topics like
His studies deal with areas such as Cervical cancer, Proportional hazards model, Median follow-up and Common Terminology Criteria for Adverse Events as well as Brachytherapy. His research investigates the connection between Internal medicine and topics such as Oncology that intersect with problems in Clinical trial. He has researched Prostate cancer in several fields, including Magnetic resonance imaging, Clinical endpoint, Prostate and Urology.
His primary areas of study are Radiation therapy, Radiology, Brachytherapy, Prostate cancer and Bladder cancer. His Radiation therapy study is concerned with Internal medicine in general. His work deals with themes such as Tumor size, Event free survival, Biochemical recurrence and Hodgkin lymphoma, which intersect with Radiology.
His study in Brachytherapy is interdisciplinary in nature, drawing from both Radiation treatment planning, Urology, Cervical cancer, Common Terminology Criteria for Adverse Events and Cohort. His work in Prostate cancer addresses issues such as Prostate, which are connected to fields such as Subclinical infection and Pelvic radiotherapy. The concepts of his Bladder cancer study are interwoven with issues in Delphi method and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker;S. Nilsson;S. Nilsson;D. Heinrich;S. I. Helle.
The New England Journal of Medicine (2013)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke.
The New England Journal of Medicine (2017)
The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
Bentzen Sm;Agrawal Rk;Aird Eg.
The Lancet (2008)
Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline.
Stephen Lutz;Lawrence Berk;Eric Chang;Edward Chow.
International Journal of Radiation Oncology Biology Physics (2011)
Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting
Louise Dickinson;Louise Dickinson;Louise Dickinson;Hashim U. Ahmed;Hashim U. Ahmed;Clare Allen;Jelle O. Barentsz.
European Urology (2011)
The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
Bentzen Sm;Agrawal Rk;Aird Eg.
Lancet Oncology (2008)
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
John Radford;Tim Illidge;Nicholas Counsell;Barry Hancock.
The New England Journal of Medicine (2015)
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.
KM Ardeshna;P Smith;A Norton;BW Hancock.
The Lancet (2003)
Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases.
P. Price;P.J. Hoskin;D. Easton;D. Austin.
Radiotherapy and Oncology (1986)
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Oliver Sartor;Robert E Coleman;Sten Nilsson;Daniel Heinrich.
Lancet Oncology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: